Bio-Path Holdings, Inc. (NASDAQ:BPTH) is on recovery track with 10.68% gain from a 1-year low price of $0.25. The company lost -7.77% to attain the price of $0.28 on 11/22/2017. Throughout the recent session, the prices were hovering between $0.272 and $0.3. These shares are 435.71% off its target price of $1.5 and the current market capitalization stands at $29.37M. The recent change has given its price a -27.51% deficit over SMA 50 and -79.91% deficit over its 52-week high. The stock witnessed -39.85% declines, 0.99% gains and -32.23% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found BPTH’s volatility during a week at 6.8% and during a month it has been found around 9.73%.Bio-Path Holdings, Inc. (BPTH) Top Holders
Institutional investors currently hold around $3 million or 9.5% in BPTH stock. Look at its top three institutional owners. University Of Texas Investment Managment Co owns $1.15 million in Bio-Path Holdings, Inc., which represents roughly 3.91% of the company’s market cap and approximately 38.3% of the institutional ownership. Similar statistics are true for the second largest owner, Vanguard Group Inc, which owns 2,238,523 shares of the stock are valued at $672 thousand. The third largest holder is Hightower Advisors, Llc, which currently holds $420 thousand worth of this stock and that ownership represents nearly 1.43% of its market capitalization.
At the end of September reporting period, 11 institutional holders increased their position in Bio-Path Holdings, Inc. (NASDAQ:BPTH) by some 640,847 shares, 20 decreased positions by 4,990,589 and 11 held positions by 5,182,326. That puts total institutional holdings at 10,813,762 shares, according to SEC filings. The stock grabbed 4 new institutional investments totaling 174,724 shares while 11 institutional investors sold out their entire positions totaling 3,974,522 shares.Bio-Path Holdings, Inc. (NASDAQ:BPTH) Insider Trades
Multiple company employees have indulged in significant insider trading. Bio-Path Holdings, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that Director Garrison Michael J. has acquired 7,343 shares of Bio-Path Holdings, Inc. (BPTH) in trading session dated Jul. 13, 2015. These shares are worth $8,958 and were traded at $1.22 each. The SEC filing shows that Garrison Michael J. performed a purchase of 8,724 shares. The Director added these shares by way of transaction on Jul. 09, 2015. The company’s shares were assimilated at $1.17 per share worth to an investment of some $10,207 on account of Garrison Michael J..
Director, Garrison Michael J., purchased 60,000 common shares of Bio-Path Holdings, Inc. (BPTH) in the open market. In a transaction dated Jul. 08, 2015, the shares were bought at an average price of $1.19, giving away a sum of $71,400. After this purchase, 892,267 common shares of BPTH are directly owned by the insider, with total stake valued at $249,835.
In the transaction dated Jun. 12, 2013, the great number of shares acquired came courtesy the Director; Garrison Michael J. added a total of 340,000 shares at an average price of $0.3, amounting to approximately $102,000. The insider now directly owns 831,667 shares worth $232,867.Bio-Path Holdings, Inc. (BPTH) Analyst Guide
Not many analysts have released their opinion on Bio-Path Holdings, Inc. (NASDAQ:BPTH), with 2 analysts believing it is a strong buy. Whereas 0 of them predict the stock is a hold. Also, there are 0 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1 average brokerage recommendation.